10,777 reports of this reaction
25.7% of all OSIMERTINIB reports
#1 most reported adverse reaction
DEATH is the #1 most commonly reported adverse reaction for OSIMERTINIB, manufactured by AstraZeneca Pharmaceuticals LP. There are 10,777 FDA adverse event reports linking OSIMERTINIB to DEATH. This represents approximately 25.7% of all 41,863 adverse event reports for this drug.
OSIMERTINIB has an overall safety score of 93 out of 100. Patients taking OSIMERTINIB who experience death should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEATH is a frequently reported adverse event for OSIMERTINIB, accounting for a significant proportion of all reports.
In addition to death, the following adverse reactions have been reported for OSIMERTINIB:
The following drugs have also been linked to death in FDA adverse event reports:
DEATH has been reported as an adverse event in 10,777 FDA reports for OSIMERTINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEATH accounts for approximately 25.7% of all adverse event reports for OSIMERTINIB, making it one of the most commonly reported side effect.
If you experience death while taking OSIMERTINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.